144 related articles for article (PubMed ID: 37330447)
1. Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma.
Spitzer HV; Kemp Bohan PM; Carpenter EL; Adams AM; Chang SC; Grunkemeier G; Vreeland TJ; Tzeng CD; Katz MHG; Nelson DW
Ann Surg Oncol; 2023 Oct; 30(11):6662-6670. PubMed ID: 37330447
[TBL] [Abstract][Full Text] [Related]
2. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival.
Altman AM; Wirth K; Marmor S; Lou E; Chang K; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Ann Surg Oncol; 2019 Nov; 26(12):4108-4116. PubMed ID: 31313044
[TBL] [Abstract][Full Text] [Related]
3. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.
Parmar AD; Vargas GM; Tamirisa NP; Sheffield KM; Riall TS
Surgery; 2014 Aug; 156(2):280-9. PubMed ID: 24851723
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma.
Mehtsun WT; McCleary NJ; Maduekwe UN; Wolpin BM; Schrag D; Wang J
JAMA Oncol; 2022 Jan; 8(1):88-95. PubMed ID: 34854874
[TBL] [Abstract][Full Text] [Related]
5. Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer.
Shapiro M; Chen Q; Huang Q; Boosalis VA; Yoon CH; Saund MS; Whang EE; Gold JS
JAMA Surg; 2016 Apr; 151(4):338-45. PubMed ID: 26581025
[TBL] [Abstract][Full Text] [Related]
6. Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I-III Pancreatic Adenocarcinoma.
Sanford NN; Aguilera TA; Folkert MR; Ahn C; Mahal BA; Zeh H; Beg MS; Mansour J; Sher DJ
J Natl Compr Canc Netw; 2019 Nov; 17(11):1292-1300. PubMed ID: 31693987
[TBL] [Abstract][Full Text] [Related]
7. Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer.
Bergquist JR; Ivanics T; Shubert CR; Habermann EB; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB; Truty MJ
Ann Surg Oncol; 2017 Jun; 24(6):1731-1738. PubMed ID: 28070725
[TBL] [Abstract][Full Text] [Related]
8. Disparities in Receipt of Adjuvant Therapy After Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma.
Anteby R; Blaszkowsky LS; Hong TS; Qadan M
Ann Surg Oncol; 2023 Apr; 30(4):2473-2481. PubMed ID: 36585536
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era.
Hue JJ; Dorth J; Sugumar K; Hardacre JM; Ammori JB; Rothermel LD; Saltzman J; Mohamed A; Selfridge JE; Bajor D; Winter JM; Ocuin LM
Am Surg; 2021 Sep; 87(9):1386-1395. PubMed ID: 34382877
[TBL] [Abstract][Full Text] [Related]
11. Adherence with operative standards in the treatment of gastric cancer in the United States.
Zhao B; Blair SL; Katz MHG; Lowy AM; Kelly KJ
Gastric Cancer; 2020 May; 23(3):550-560. PubMed ID: 31745679
[TBL] [Abstract][Full Text] [Related]
12. Application of Guideline Recommended Treatment in Routine Clinical Practice: A Population-based Study of Stage I-IIIB Non-small Cell Lung Cancer.
Duggan KJ; Descallar J; Vinod SK
Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):639-47. PubMed ID: 27211609
[TBL] [Abstract][Full Text] [Related]
13. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
14. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database.
Hamad A; Underhill J; Ansari A; Thayaparan V; Cloyd JM; Li Y; Pawlik TM; Tsung A; Abushahin L; Ejaz A
Surgery; 2022 Jun; 171(6):1464-1470. PubMed ID: 35115154
[TBL] [Abstract][Full Text] [Related]
15. National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection.
Ellis RJ; Ho JW; Schlick CJR; Merkow RP; Bentrem DJ; Bilimoria KY; Yang AD
Ann Surg Oncol; 2020 Mar; 27(3):909-918. PubMed ID: 31691112
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for margin positive pancreatic cancer: A propensity score matched analysis.
Takahashi C; Shridhar R; Huston J; Meredith K
Pancreatology; 2022 Apr; 22(3):396-400. PubMed ID: 35304103
[TBL] [Abstract][Full Text] [Related]
17. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
[TBL] [Abstract][Full Text] [Related]
18. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
[TBL] [Abstract][Full Text] [Related]
19. Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters.
Valdera FA; O'Shea AE; Smolinsky TR; Carpenter EL; Adams AA; McCarthy PM; Tiwari A; Chick RC; Kemp-Bohan PM; Van Decar S; Thomas KK; Bader JO; Peoples GE; Clifton GT; Stojadinovic A; Nelson DW; Vreeland TJ
J Surg Oncol; 2024 Feb; 129(2):244-253. PubMed ID: 37800378
[TBL] [Abstract][Full Text] [Related]
20. Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer.
Kagedan DJ; Abraham L; Goyert N; Li Q; Paszat LF; Kiss A; Earle CC; Mittmann N; Coburn NG
Cancer; 2016 Oct; 122(20):3175-3182. PubMed ID: 27391466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
